股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥捷安康 (南京 )科技股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02617 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | | 增加 / 減少 (-) | | | 2,100,000 | | | RMB | | 2,100,000 | | 本月底結存 | | | 303,766,673 | RMB | | 1 RMB | | 303,766,673 | 足夠公眾持股量的確認 ...

配售事项所得款项总额约为1.95亿港元，而配售事项所得款项净额(经扣除配售佣金及配售事项的其他 相关成本及开支后)约为1.9亿港元。按此基准，净发行价约为每股配售股份90.54港元。 本公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所得款项净额的约 60%，或约1.14亿港元，用于为我们的核心产品Tinengotinib在中国正在进行单药治疗胆管癌(CCA)的临 床试验以及我们核心产品的其他适应症的研发提供资金;配售事项所得款项净额的约30%，或约5704万 港元，用于其他产品的研发，包括TT-00973、TT-01488及其他分子;及配售事项所得款项净额的约 10%，或约1901万港元，用于营运资金及一般企业用途。 210万股配售股份相当于紧接完成前现有已发行H股数目的约0.70%及本公司现有已发行股份数目的约 0.53%，及相当于经配发及发行配售股份扩大后的已发行H股数目的约0.69%及本公司已发行股份数目的 约0.53%。 药捷安康-B(02617)发布公告，配售协议所载所有条件已获达成，而完成已于2026年1月20日落实。配售 代理已按配售价每股配售股份92.85港元成功向不少 ...

智通财经APP讯，药捷安康-B(02617)发布公告，配售协议所载所有条件已获达成，而完成已于2026年1 月20日落实。配售代理已按配售价每股配售股份92.85港元成功向不少于六名承配人配售合共210万股配 售股份。 配售事项所得款项总额约为1.95亿港元，而配售事项所得款项净额(经扣除配售佣金及配售事项的其他 相关成本及开支后)约为1.9亿港元。按此基准，净发行价约为每股配售股份90.54港元。 本公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所得款项净额的约 60%，或约1.14亿港元，用于为我们的核心产品Tinengotinib在中国正在进行单药治疗胆管癌(CCA)的临 床试验以及我们核心产品的其他适应症的研发提供资金;配售事项所得款项净额的约30%，或约5704万 港元，用于其他产品的研发，包括TT-00973、TT-01488及其他分子;及配售事项所得款项净额的约 10%，或约1901万港元，用于营运资金及一般企业用途。 210万股配售股份相当于紧接完成前现有已发行H股数目的约0.70%及本公司现有已发行股份数目的约 0.53%，及相当于经配发及发行配售股份扩大后的已发行H ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； FF305 公司名稱： 藥捷安康(南京)科技股份有限公司 呈交日期： 2026年1月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 茲提述藥捷安康（南京）科技股份有限公司（「本公司」）日期為2026年1月14日的公 告（「該公告」），內容有關配售事項。除文義另有所指外，本公告所用詞彙與該公 告所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售任何證券的要約或招攬購買或認購任何證券的任何要約。除非已根據1933年美國證券法（經 修訂）登記或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開 發售將僅以招股章程的方式進行，有關招股章程可向證券發行人或賣方取得，並載有發行人及 其管理層的詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 TransThera Sciences (Nan ...

Group 1 - Hong Kong's Hang Seng Index fell by 0.04%, down 11 points, closing at 26,552 points, while the Hang Seng Tech Index decreased by 0.66% with a trading volume of HKD 129.8 billion in the morning session [1] - Pop Mart (09992) surged over 8% as the company repurchased shares worth HKD 251 million [1] - Major airlines continued to rise, with strong expectations for industry growth; China Southern Airlines (01055) increased by 3.72%, China Eastern Airlines (00670) by 4.56%, and Air China (00753) by 2.5% [1] Group 2 - Weisheng Holdings (03393) rose nearly 9%, reaching new highs as the State Grid increased its investment scale, indicating a favorable phase for smart meter investments [2] - Health Road (02587) increased by over 4% after the controlling shareholder extended the lock-up period, and the company repurchased 327,000 shares recently [3] - Blucube (00325) rose against the trend by 3.95%, benefiting from the expansion of China's trendy toy industry and the enrichment of its IP system and product matrix [4] Group 3 - Hou Shang Ayi (02589) saw a rise of over 10% as its 25-year performance forecast exceeded expectations, with net profit expected to grow by up to 60% year-on-year [5] - Gigadevice (03986) increased by over 5%, reaching a new high as Micron reported worsening shortages of memory chips, indicating that supply tightness will persist beyond this year [6] - Damai Entertainment (01060) rose over 4% after announcing its entry into the museum sector, positioning itself to benefit from the upgrading of consumer structures [7] Group 4 - The commercial aerospace sector experienced declines, with Asia Pacific Satellite (01045) dropping by 6.9% and Goldwind Technology (02208) falling by over 3% [8] - Jiayuan Ankang-B (02617) fell over 9% as it proposed a placement to raise HKD 190 million, primarily for core product development [9]

Group 1 - The insurance sector saw significant gains, with China Life (02628) up 3.81%, China Pacific Insurance (02601) up 2.31%, and Ping An (02318) up 1.17%. Notably, major insurance companies reported a doubling in premium income through bancassurance channels as of January 8, 2026 [1] - The commercial aerospace sector experienced a notable decline, with companies like JunDa Co. (02865) down 7.19% and Asia Pacific Satellite (01045) down 5.94%. This follows a period of intense adjustments and risk warnings from several listed companies in the sector [1] - The real estate sector showed active performance, with companies like R&F Properties (02777) up 4% and Greentown China (03900) up 5.79%. Data from the National Bureau of Statistics indicated a 0.3% month-on-month decline in new residential sales prices in first-tier cities for December 2025, a slight improvement from the previous month [2] Group 2 - HuShang Ayi (02589) reported an expected net profit of 495 million to 525 million RMB for 2025, reflecting a year-on-year growth of 50% to 60% [3] - Yi Communications Group (08031) saw a surge of over 70% upon resuming trading, with a current increase of 53.85%. The company announced a share acquisition deal involving 210 million shares at a price of 0.276 HKD per share, which is a 15.08% discount from the pre-suspension closing price [3] - Guorui Life (00108) experienced an increase of over 11% after announcing a deal to acquire 78.29% of Chunyu Doctor for 269 million RMB, marking its entry into the digital healthcare sector [4]

每经AI快讯，药捷安康-B(02617.HK)一度跌超10%，截至发稿跌9.02%，报84.7港元，成交额1.17亿港 元。 ...

消息面上，药捷安康此前宣布，拟配售2100万股新股份，每股配售价92.85港元，较1月13日H股收市价 113.2港元折让17.98%，所得款项净额1.9亿港元。其中，60%用于为其核心产品Tinengotinib在中国正在 进行单药治疗胆管癌(CCA)的临床试验以及核心产品的其他适应症的研发提供资金；约30%用于其他产 品的研发，包括TT-00973、TT-01488及其他分子；约10%用于营运资金及一般企业用途。 药捷安康-B(02617)再跌超10%，截至发稿，跌9.02%，报84.7港元，成交额1.17亿港元。 ...

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a decline of over 10%, currently trading at 84.7 HKD, with a transaction volume of 117 million HKD [1] Group 1: Stock Performance - Zymeworks Inc. shares fell by 9.02% to 84.7 HKD as of the latest report [1] - The stock has seen a significant drop following the announcement of a new share placement [1] Group 2: Share Placement Announcement - The company plans to place 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The net proceeds from the placement are expected to be 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]